Advantage Alpha Capital Partners LP Takes $386,000 Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Advantage Alpha Capital Partners LP purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the third quarter, Holdings Channel reports. The institutional investor purchased 10,737 shares of the company’s stock, valued at approximately $386,000.

Other large investors have also recently bought and sold shares of the company. FMR LLC grew its stake in Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after acquiring an additional 3,707,734 shares in the last quarter. RA Capital Management L.P. acquired a new position in Dyne Therapeutics in the 1st quarter valued at approximately $140,666,000. Vanguard Group Inc. lifted its position in Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after buying an additional 1,110,629 shares in the last quarter. Artal Group S.A. lifted its position in Dyne Therapeutics by 24.6% in the 1st quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after buying an additional 300,000 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Dyne Therapeutics by 1.5% during the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after acquiring an additional 19,730 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Down 0.7 %

NASDAQ DYN opened at $29.23 on Wednesday. Dyne Therapeutics, Inc. has a 1 year low of $10.12 and a 1 year high of $47.45. The company has a fifty day simple moving average of $32.06 and a 200 day simple moving average of $35.40.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DYN has been the subject of several recent research reports. Stifel Nicolaus increased their price objective on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Chardan Capital reiterated a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Oppenheimer restated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $50.82.

Insider Activity at Dyne Therapeutics

In related news, COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the transaction, the chief operating officer now directly owns 131,636 shares in the company, valued at $4,529,594.76. The trade was a 6.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO John Cox purchased 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was purchased at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. This represents a -133.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 176,257 shares of company stock worth $6,193,718 in the last 90 days. 20.77% of the stock is owned by company insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.